Loading clinical trials...

A Study of SEA-CD40 Given With Other Drugs in Cancers | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of SEA-CD40 Given With Other Drugs in Cancers

An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies

NCT04993677•Seagen Inc.

Summary

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically confirmed unresectable malignancy defined as one of the following:
•* Cohort 1: Relapsed and/or refractory metastatic melanoma
•* Uveal/ocular melanoma is excluded
•* Must have progressed on treatment with an anti-PD-(L)1 mAb. PD-(L)1 treatment progression is defined as meeting all of the following criteria:
•* Has received at least 2 doses of an approved anti-PD-(L)1 mAb
•* Has demonstrated disease progression after PD-(L)1 as defined by RECIST v1.1.
•* Progressive disease has been documented within 12 weeks from the last dose of anti- PD-(L)1 mAb
•* Last dose of anti-PD-(L)1 must have been within 90 days prior to enrollment
•* Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or declined treatment with BRAF/MEK targeted therapy prior to study entry
•* Cohort 2: Metastatic uveal melanoma
+15 more criteria

Exclusion Criteria

•History of another malignancy within 3 years of first dose of study drug
•Active central nervous system (CNS) metastases and/or carcinomatous meningitis.
•Previous exposure to CD40-targeted therapy
•Currently on chronic systemic steroids in excess of physiologic replacement
•Has had an allogeneic tissue/solid organ transplant.
•History of autoimmune disease that has required systemic treatment in the past 2 years

Locations (29)

Highlands Oncology Group

Springdale, Arkansas, United States

The Angeles Clinic and Research Institute

Los Angeles, California, United States

California Pacific Medical Center Research Institute/Sutter Medical Centre

San Francisco, California, United States

University of California at San Francisco

San Francisco, California, United States

Florida Cancer Specialists - South Region

Fort Myers, Florida, United States

Florida Cancer Specialists - North Region

St. Petersburg, Florida, United States

University Cancer & Blood Center, LLC

Athens, Georgia, United States

Rush University Medical Center

Chicago, Illinois, United States

Community Health Network

Indianapolis, Indiana, United States

American Oncology Networks LLC

Baton Rouge, Louisiana, United States

Key Dates

Start Date

October 6, 2021

Primary Completion Date

January 3, 2024

Completion Date

November 25, 2024

Last Updated

May 11, 2025

Enrollment

ACTUAL participants

Conditions

MelanomaCarcinoma, Non-Small- Cell Lung

Interventions

SEA-CD40

DRUG

pembrolizumab (KEYTRUDA®)

DRUG

pemetrexed

DRUG

carboplatin

DRUG

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of SEA-CD40 Given With Other Drugs in Cancers

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma